Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT) from its SEC filings: 2025 revenue $175.1 million (+217% vs the year before), net margin -0%, free cash flow -$167.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $175.1 million |
| Revenue growth | +217% |
| Net income | -$221,250 |
| Net margin | -0.1% |
| Free cash flow | -$167.0 million |
| Diluted EPS | $-3.03 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +88% |
| Cash | $182.5 million |
| Long-term debt | $164.6 million |
| Share count, 1 year | +14% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.